FDA finds no evidence GLP-1 drugs cause suicidal thoughts

The U.S. Food and Drug Administration said its preliminary evaluation of reports of suicidal thoughts or actions in people taking GLP-1 receptor agonists "has not found evidence that use of these medicines causes suicidal thoughts or actions" ^[1]. The agency shared the finding in a Drug Safety Communication dated January 11, 2024, and said its review was continuing ^[1].

The class covered includes semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound), along with older drugs such as exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), lixisenatide (Adlyxin) and the insulin combinations Xultophy and Soliqua ^[1]. FDA noted that tirzepatide is a dual GIP and GLP-1 receptor agonist, not a pure GLP-1 drug ^[1]. The first GLP-1 drug in the class was approved in 2005 ^[1].

What the FDA reviewed

Over several months, FDA conducted detailed reviews of reports submitted to the FDA Adverse Event Reporting System, known as FAERS ^[1]. The agency said the information in those reports "was often limited" and that such events can be influenced by other factors, so the reports "did not demonstrate a clear relationship" with GLP-1 use ^[1].

FDA also looked at clinical trial data, including large cardiovascular and other outcome studies, plus observational studies, and said those reviews "did not find an association" between GLP-1 drugs and suicidal thoughts or actions ^[1].

The agency added an important caveat. Because the number of suicidal thoughts or actions was small in both the groups taking GLP-1 drugs and the comparison control groups, FDA said it "cannot definitively rule out that a small risk may exist" ^[1]. That is why the review stayed open ^[1].

Two additional analyses were underway at the time: a meta-analysis combining clinical trial findings across all GLP-1 products, and an analysis of postmarketing data in the Sentinel System, a large network of health insurance claims and patient health records used to investigate drug safety questions ^[1]. FDA said it would communicate final conclusions and recommendations after completing the review or when it had more information to share ^[1].

What the labels said at the time

FDA pointed out that prescribing information for GLP-1 drugs approved for obesity or overweight already contained information about the risk of suicidal thoughts and actions ^[1]. That warning language also appears in labels for other weight-loss medicines and came from reports seen with a variety of older drugs used or tested for weight loss, not from new findings specific to this class ^[1].

FDA told health care professionals to monitor patients and advise them to report new or worsening depression, suicidal thoughts, or unusual changes in mood or behavior ^[1]. It told patients not to stop taking GLP-1 drugs without first consulting a health care professional, because stopping can worsen the underlying condition, and to talk to a clinician with questions ^[1]. The agency also pointed to the 988 Suicide and Crisis Lifeline, which can be reached by call or text at 988 or at 988lifeline.org, and which provides free support 24 hours a day, seven days a week ^[1].

Why it matters for patients

Reports of suicidal thoughts in people taking semaglutide and similar drugs drew heavy news coverage and prompted regulatory reviews on both sides of the Atlantic. This communication was the first public statement from FDA summarizing what its own data review had turned up, and the answer was that the agency had not found a causal link in either spontaneous reports or trial data ^[1].

At the same time, the finding was labeled preliminary, and FDA was explicit that the events were rare enough in both treatment and control groups that a small risk could not be excluded ^[1]. In practical terms, that meant the boxed label language about mood changes stayed in place for the obesity products, and clinicians were still expected to ask about depression and mood changes at follow-up visits ^[1].

The communication does not give patient counts, rates, or the number of FAERS reports reviewed, and it does not name the individual trials examined. Those details are not in the source.

What happens next

FDA said it would report final conclusions once the meta-analysis and Sentinel analysis were done, without giving a date ^[1]. The agency's page now carries a notice that FDA issued a further Drug Safety Communication on January 13, 2026, requesting removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications ^[1]. Details of that later action are not included in this source.